Here is the design of a clinical trial:

Official Title: Prophylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation

Included conditions:
- Atrial Fibrillation

Study Armgroups:
- {'label': 'Intervention Arm', 'type': 'EXPERIMENTAL', 'description': 'Patients randomized to amiodarone treatment', 'interventionNames': ['Drug: Amiodarone']}
- {'label': 'Control Arm', 'type': 'PLACEBO_COMPARATOR', 'description': 'Patients randomized to placebo treatment', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Amiodarone', 'description': 'Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:\n\n• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:\n\n* If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).\n* If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first).', 'armGroupLabels': ['Intervention Arm']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:\n\n* All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:\n\n  o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).\n* Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first).', 'armGroupLabels': ['Control Arm']}

Primary Outcomes:
- {'measure': 'Capability for enrolment', 'description': 'Capacity for enrolment will be assessed, in order to determine recruitment potential and an optimal sample size estimated for a full-scale RCT, by measuring the following outcomes: proportion of patients risk stratified and screened, proportion of eligible individuals consenting to involvement in the study, proportion of recruited individuals who are enrolled in the study.', 'timeFrame': 'Upon study completion, 1 year following study initiation'}
- {'measure': 'Proportion of patients randomized who receive the intervention', 'description': 'Feasibility of the randomization process will be evaluated including the proportion of patients randomized who receive the intervention', 'timeFrame': 'Upon study completion, 1 year following study initiation'}
- {'measure': 'Knowledge of which patients received intervention and placebo', 'description': 'Feasibility of blinding of participant, care provider, investigator, and outcomes assessor to the intervention allocation of participants will be evaluated by administering a survey to assess their knowledge of which patients received the intervention and placebo', 'timeFrame': 'Upon study completion, 1 year following study initiation'}
- {'measure': 'Intervention delivery', 'description': 'Intervention delivery will be assessed by determining if protocol adherence rates exceed \\>90% and recording observational data on the quality of intervention delivery using a data collection sheet', 'timeFrame': 'Upon study completion, 1 year following study initiation'}
- {'measure': 'Protocol compliance', 'description': 'Monitoring of protocol compliance will be measured by the frequency, rate, and rationale of events when study activities diverge from the REB-approved protocol', 'timeFrame': 'Upon study completion, 1 year following study initiation'}
- {'measure': 'Adherence to safety protocol', 'description': 'Monitoring of safety will be assessed by determining the rate and efficiency of reporting adverse events if they occur and monitoring adherence rates to safety and monitoring protocols', 'timeFrame': 'Upon study completion, 1 year following study initiation'}
- {'measure': 'Proportion of patients for which data could be abstracted', 'description': 'Feasibility of data extraction analysis will be evaluated by the proportion of patients for which the required data could be abstracted: medication use, incidence of post-operative atrial fibrillation, post-operative outcomes, etc.', 'timeFrame': 'Upon study completion, 1 year following study initiation'}
- {'measure': 'Resources', 'description': 'Resources required to conduct a future multi-centre PREP-AF trial will be assessed by evaluating the administrative capacity of the POAF research team, including the required number of hours of research assistant time, as well as the feasibility of the designated study budget', 'timeFrame': 'Upon study completion, 1 year following study initiation'}

Please estimate the sample size based on the assumption: 
No specific assumptions on significance level, power, or missing/dropout rate were made.
Sample size {14}
          No sample size calculation was conducted for this feasibility study. We aim to recruit 80 patients for randomization during this 12-month trial. Our institution conducts approximately 200 major thoracic surgeries annually and we anticipate 100 of those patients to be eligible for inclusion based on POAF risk and assume a recruitment rate of 80. Patients will follow the schedule activities described in the âParticipant timeline {13}â section including a 30-day follow-up.